Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$2.08 USD
+0.03 (1.46%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $2.09 +0.01 (0.48%) 4:40 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DARE 2.08 +0.03(1.46%)
Will DARE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DARE
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates
DARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
Other News for DARE
Is DARE poised for gains? Boomer Buy Setup shows up after sinking 2.15%
Is DARE preparing to trend higher? Crossed Above 20 Day Moving Average shows up after advancing 3.2%
Is DARE preparing to trend higher? 1,2,3 Pullback Bullish shows up after slipping 3.79%
Is DARE showing upside potential? 20 Day Moving Average Support shows up after a flat session
Is DARE positioned for a breakout? Boomer Buy Setup shows up after dropping 0.94%